


ELUVIA™ Drug-Eluting Vascular Stent System


96.1%
PRIMARY PATENCY
AT 12 MONTHS

Pushing patency beyond bare-metal and drug-coated stents

12-Month Primary Patency



12-Month Target Lesion Revascularization (TLR) Rate



Results from different trials are not directly comparable. Information provided for educational purposes.

1. Data obtained from product SED found on www.fda.com on 7Dec2015. Primary patency defined as a binary duplex ultrasound ratio < 2.4 at the stented target lesion with no clinically-driven reintervention without the stented segment. n=287


2. Data obtained from product SED found on www.fda.com on 7Dec2015. Primary patency defined as PSVR ratio of ≤ 2.4 . n=264.

3. Laird J, et al. Circ Cardiovasc Intervention. 2010;3:267-276. Primary patency defined as PSVR ≥ 2.5 . n=206

4. Kaplan-Meier estimate of 12-month primary patency. Data obtained from product SED found on www.fda.com on 7Dec2015. Primary patency defined as PSV ratio of < 2.0. n=471


5. Müller-Hülsbeck, S. Presented at CIRSE 2015. Primary patency defined as PSVR ≤ 2.5 and the absence of TLR or bypass. n=57

The Challenge: A Harsh SFA Environment



Significant mechanical forces in the SFA prolong the response to injury and make the SFA susceptible to restenosis.

CLINICAL HISTORY OF RESTENOSIS




Restenosis following nitinol stenting peaks at about 12 months in the SFA

The Solution: Sustained Drug Release

The Eluvia™ Stent, with Sustend™ drug-delivery technology, is designed to deliver paclitaxel when restenosis is most likely to occur.

Polymer-based technology with proven biocompatibility¹

- Implanted in more than 10 million vessels since 2007
- More than 20,000 patients studied in clinical trials




* Based on pre-clinical PK analysis. Data on file at Boston Scientific. Dake MD, et al. J Vasc Interv Radiol. 2011;22(5):603-610.

Built on the Innova™ Stent platform, designed to optimize:

- Flexibility
- Radial strength
- Fracture resistance

While providing uniform scaffolding for drug delivery.



The Outcome: **UNPRECEDENTED** Results in the SFA

MAJESTIC CLINICAL TRIAL

TRIAL OVERVIEW


- Core lab adjudicated single-arm, multicenter trial (n=57)
- 65% of lesions severely calcified
- 46% total occlusions
- 71 mm average lesion length

12-MONTH RESULTS

96.1% Primary Patency¹

TLR: 3.8%


0 STENT FRACTURES



1. Primary patency defined as duplex ultrasound PSVR ≤ 2.5 and absence of TLR or bypass. Data on file at Boston Scientific.

ELUVIA™ Drug Eluting Vascular Stent System

Triaxial delivery system for more precise and predictable stent placement



		Stent diameter (mm)				
		6		7		
		Delivery system working length (cm)				
		75	130	75	130	
Stent Length (mm)	40	H74939295600470	H74939295600410	H74939295700470	H74939295700410	6 / 2.0
	60	H74939295600670	H74939295600610	H74939295700670	H74939295700610	6 / 2.0
	80	H74939295600870	H74939295600810	H74939295700870	H74939295700810	6 / 2.0
	100	H74939295601070	H74939295601010	H74939295701070	H74939295701010	6 / 2.0
	120	H74939295601270	H74939295601210	H74939295701270	H74939295701210	6 / 2.0
	150	H74939295601570	H74939295601510	H74939295701570	H74939295701510	6 / 2.0

CAUTION: The law restricts these devices to sale by or on the order of a physician. Indications, , warnings and instructions for use can be found in the product labeling supplied with each device. Information for the use only in countries with applicable health authority product registrations. This material is not for use or distribution in France. Eluvia is a registered or unregistered trademark of Boston Scientific Corporation or its affiliates. All other trademarks are property of their respective owners.

© 2016 Boston Scientific Corporation or its affiliates. All rights reserved. PI-349603-AA JAN2016 DINPER4672EA